Overview

Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory), or myelodysplastic syndrome. Natural killer cells are a type of immune cell. Immunotherapy with genetically modified NK cells from donors may induce changes in the body?s immune system and may interfere with the ability of cancer cells to grow and spread.

Phase:

Phase 1

Details

Lead Sponsor:

Sumithira Vasu

Collaborator:

National Cancer Institute (NCI)

Treatments:

Cytarabine
Decitabine
Fludarabine
Fludarabine phosphate
Vidarabine